RT Journal Article SR Electronic T1 Safety and immunogenicity of COReNAPCIN®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.11.01.23297898 DO 10.1101/2023.11.01.23297898 A1 Salehi, Mohammadreza A1 Darazam, Ilad Alavi A1 Nematollahi, Alireza A1 Alimohammadi, Masoumeh A1 Pouya, Sedigheh A1 Alimohammadi, Reza A1 Khajavirad, Nasim A1 Porgoo, Meysam A1 Sedghi, Mosslim A1 Sepahi, Mohammad Mahdi A1 Azimi, Maryam A1 Hosseini, Hamed A1 Hashemi, Seyed Mahmoud A1 Dehghanizadeh, Somaye A1 Khoddami, Vahid YR 2023 UL http://medrxiv.org/content/early/2023/11/02/2023.11.01.23297898.abstract AB The repeated COVID-19 outbreaks, despite global vaccination, highlights the need for booster doses. Here, we present the outcomes, up until day 90 post vaccination, of a randomized, double-blind, placebo-controlled phase 1 clinical trial of the mRNA-based vaccine candidate; COReNAPCIN®, as a booster dose in adults aged 18-50 who had previously received three doses of inactivated vaccines. In the study, 30 participants randomly (2:2:1) received 25 μg, or 50 μg of COReNAPCIN®, or placebo. The results indicated that COReNAPCIN® was well tolerated in vaccinated individuals in both groups with no life-threatening or other serious adverse events. The most noticeable solicited adverse events were pain at the site of injection, fatigue and myalgia. Regarding the immunogenicity, given the seroprevalence of SARS-CoV-2 antibodies due to the vaccination history for all, and previous SARS-CoV-2 infection for some participants, the recipients of COReNAPCIN®, two weeks post vaccination, showed significant fold increases in the level of anti-RBD (6.6 and 8.1 folds) or anti-spike (11.5 and 21.7 folds), and potent neutralizing antibodies (10.2 and 8.4 folds) in 25 and 50 μg groups, respectively, while no meaningful changes were observed in the placebo group. Additionally, the significant increase in the spike-specific IFN-γ T-cell response upon vaccination, underscores the activation of cellular immunity. Altogether, the favorable safety, tolerability, and immunogenicity profile of COReNAPCIN® support its further clinical development.Trial registration number IRCT20230131057293N1Competing Interest StatementThe authors V.K., and S.D. are management board member and employees at ReNAP Therapeutics. M.A., S.P., M.P., M.S., and M.M.S. are current employees at ReNAP Therapeutics. A.N., and R.A. are former employees at ReNAP Therapeutics. M.S. and S.M.H. are members of the Iran national committee of COVID-19 vaccination. The authors declare that they have no other relationships or activities that could have influenced the submitted manuscript.Clinical TrialIRCT20230131057293N1Funding StatementWe acknowledge the Iran National Innovation Fund (INIF) for financial support for this study, and Ministry of Health and Medical Education, Iran Food and Drug Administration (IFDA), Iran National Committee for Ethics in Biomedical Research, and Vice-presidency for Science and Technology (VPST), for all their support for this clinical trial. The authors would like to thank Professor Hossein Ghanaati, president of the Tehran University of Medical Sciences, for his valuable support, and the dedicated nurses of the Mahdi Clinic of the Imam Khomeini Hospital Complex (Tehran, Iran), where this study was conducted and all clinical trial coordinators. We sincerely thank all the volunteers who generously participated in this study. We would also like to thank the Noor Pathobiology and Genetic Laboratory and the Amirabad Laboratory for masked laboratory assessment of clinical samples of this study. We appreciate efforts of the members of the Data and Safety Monitoring Board (DSMB) for their careful evaluation of the clinical trial outcomes. We are also very grateful for the collaboration with AryoGen Pharmed, which contributed to the GMP-compliant manufacturing of COReNAPCIN®, and Pharmed Pajoohan Viera, as the contract research organization (CRO), for their participation in the design and conduct of this clinical trial. We also acknowledge all staff members of ReNAP Therapeutics who participated in logistics, procurement, production, quality assurance and quality control of COReNAPCIN® and Placebo vials for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Iran National Committee for Ethics in Biomedical Research gave ethical approval for this work (IR.NREC.1401.007).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes